A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression

This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.

Study Overview

• Status: Completed
• Conditions: Breast Neoplasms; Solid Tumors; Gastric Neoplasm
• Intervention / Treatment: Drug: ARX788

Detailed Description

Phase 1a will determine the recommended Phase 2 dose (RP2D) in subjects with advanced cancer whose HER2 test results are in situ hybridization (ISH) positive or immunohistochemistry (IHC) 3+, based on safety, tolerability, PK findings and antitumor activity. Phase 1b will assess the safety, tolerability, and PK and anticancer activity in five expansion cohorts, including breast cancer, gastric cancer / gastroesophageal adenocarcinoma, and other advanced HER2-positive solid tumors.

• Study Type: Interventional
• Enrollment (Actual): 106
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • East Albury, New South Wales, Australia, 2640
      • Research Site
    • North Sydney, New South Wales, Australia, 2640
      • Research Site
  • Queensland
    • South Brisbane, Queensland, Australia, 4101
      • Mater Misericordiae Limited
    • Woolloongabba, Queensland, Australia, 4102
      • Princess Alexandria Hospital
  • Victoria
    • Clayton, Victoria, Australia, 3168
      • Monash Health
    • Frankston, Victoria, Australia, 3199
      • Research Site
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • Research Site
• United States
  • California
    • Los Angeles, California, United States, 90033
      • USC Norris Cancer Hospital
    • Santa Monica, California, United States, 90095
      • UCLA Hematology-Oncology
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic
  • Texas
    • Dallas, Texas, United States, 75246
      • Baylor Sammons Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age >18 years
• Life expectancy >3 months.
• Female or male subjects whose advanced HER2 expressing cancer has failed standard of care treatments, or for whom such therapy is not acceptable to the subject. Subjects with advanced breast, gastric cancer, or other solid tumor who test positive for HER2 by ASCO/CAP criteria (either IHC or FISH) must have received prior treatment with a trastuzumab containing therapy. Subjects who have been previously treated with pertuzumab, TDM-1, lapatinib, or other available and accessible HER2-directed therapies or investigational therapies are eligible.

• Disease measurability:

  • Phase 1a: measurable or non-measurable disease per RECIST v 1.1.
  • Phase 1b: measurable disease per RECIST v 1.1 (subjects with non-measurable disease are not eligible for Phase 1b).
• Histopathologic evidence of cancer based upon pathology report.

• Tumor tissue local laboratory HER2 testing results, adequate tumor sample available for confirmation of HER2 status. Subjects with other types of cancer must have previously tested locally for HER2 status by HER2 IHC or ISH assay.

  • Phase 1a: ISH positive or IHC 3+ advanced cancer (including breast or gastric/esophageal or other solid tumors).
  • Phase 1b: Cohort 8 advanced breast cancer (IHC 3+ or IHC 2+/ISH); Cohort 9 advanced breast cancer (IHC 2+ / ISH-); Cohort 10 advanced gastric cancer (IHC 3+ or IHC 2+/ISH+) or gastroesophageal junction adenocarcinoma; Cohort 11 other advanced solid tumor cancers with HER2-overexpression (HER2 IHC 3+ or IHC 2+/IHS+); Cohort 12 advanced solid tumor cancers with HER2 activating mutation.
• Eastern Cooperative Oncology Group Performance Status of 0 to 1.
• Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 as per the NCI-CTCAE v 4.03 (phase 1a) and v 5.0 ( Phase 1b).
• Adequate organ functions.
• Willing and able to understand and sign an informed consent inform and to comply with all aspects of the protocol.
• Female subjects must be surgically sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or who commits to use an acceptable form of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 3 months following the last dose of study treatment.
• Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study.

Exclusion Criteria:

• History of allergic reactions to any component of ARX788.
• History of ocular events, or any current ongoing active ocular infections.
• History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia within 12 months prior to enrollment
• Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 5.0)
• History of unstable central nervous system (CNS) metastases
• Current severe, uncontrolled systemic disease (eg, clinical significant cardiovascular, pulmonary, or metabolic diseases)
• Any uncontrollable intercurrent illness, infection (including subjects with active, symptomatic Covid-19 infections), or other conditions that could limit study compliance or interfere with assessments.
• Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of ARX788.
• Clinically significant surgical intervention (excluding diagnostic biopsy) within 21 days of the first dose of ARX788
• Radiotherapy administered less than 21 days prior to the first dose of ARX788, or localized palliative radiotherapy administered less than 7 days prior to the first dose of ARX788, or radiotherapy-induced toxicity of Grade 2 or greater based on NCI-CTCAE v 5.0.
• Pregnancy or breast feeding.
• Known active HCV, HBV, and/or HIV infection.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ARX788 Phase 1a (Dose Escalation); ARX788 will be administered every 3 weeks (Q3W) or every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will be enrolled into escalating dose levels during Dose Escalation period.	Drug: ARX788; An antibody drug conjugate; Other Names: antibody drug conjugate (ADC)
Experimental: ARX788 Phase 1b (Dose Expansion); ARX788 will be administered every 3 weeks (Q3W) via intravenous (IV) infusion. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.	Drug: ARX788; An antibody drug conjugate; Other Names: antibody drug conjugate (ADC)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects experiencing adverse events, frequency and seriousness of treatment emergent adverse events (TEAEs)	To assess the safety, tolerability, and immunogenicity profile	Day 1 through 30 days after last dose
Phase 1b: Objective response rate (ORR: complete response + partial response) per imaging assessment based on RECIST version 1.1.	Number of subjects with objective response is assessed every 6-8 weeks from Cycle 1 Day 1 through disease progression.	36 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects with tumor response per imaging assessment based on RECIST version 1.1.	The objective response rate (ORR: CR+PR) based on RECIST v1.1 will be assessed as the primary endpoint to determine the anticancer activity of ARX788 as well as best overall response.	18 months
Area under the concentration-time curve (AUC) from first infusion to subject end of study.	Pharmacokinetic (PK) characteristics: ARX788 (intact ADC), total mAb, and metabolites	36 months
Half-life of ARX788 from first infusion to end of study.	Pharmacokinetic (PK) characteristics: ARX788 from first infusion to subject end of study	36 months
Immunogenicity profile of ARX788	Number of subjects who develop anti-ARX788 antibody	36 months

Collaborators and Investigators

• Sponsor: Ambrx, Inc.
• Investigators: Study Director: Ambrx, Ambrx, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 20, 2018
• Primary Completion (Actual): September 13, 2023
• Study Completion (Actual): October 18, 2023

Study Registration Dates

• First Submitted: August 14, 2017
• First Submitted That Met QC Criteria: August 16, 2017
• First Posted (Actual): August 21, 2017

Study Record Updates

• Last Update Posted (Actual): February 1, 2024
• Last Update Submitted That Met QC Criteria: January 31, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: breast cancer; HER2; gastric cancer; advanced solid tumors; antibody drug conjugate; HER2-overexpression; HER2-mutations
• Additional Relevant MeSH Terms: Digestive System Diseases; Skin Diseases; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Breast Diseases; Neoplasms; Stomach Neoplasms; Breast Neoplasms; Physiological Effects of Drugs; Immunologic Factors; Immunoconjugates
• Other Study ID Numbers: ARX788-1711

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No